Laboratory and clinical characteristics
| . | At baseline . | After 12 months of HU . |
|---|---|---|
| Median PLT, ×109/L (range) | 906 (258-3920) | 494 (149-1356) |
| Less than 400 × 109/L, n (%) | 5 (1) | 107 (26) |
| 400-600 × 109/L, n (%) | 16 (4) | 237 (57) |
| More than 600 × 109/L, n (%) | 395 (95) | 72 (17) |
| Median WBC, ×109/L (range) | 9.4 (4.2-34) | 6.7 (3.2-28.9) |
| Less than 10 × 109/L, n (%) | 267 (64) | 371 (89) |
| More than 10 × 109/L, n (%) | 149 (36) | 45 (11) |
| Aspirin-resistant microvascular symptoms, n (%) | ||
| No | 313 (75) | 368 (88) |
| Yes | 103 (25) | 48 (12) |
| Splenomegaly, n (%) | ||
| No | 359 (86) | 381 (92) |
| Yes | 57 (14) | 35 (8) |
| . | At baseline . | After 12 months of HU . |
|---|---|---|
| Median PLT, ×109/L (range) | 906 (258-3920) | 494 (149-1356) |
| Less than 400 × 109/L, n (%) | 5 (1) | 107 (26) |
| 400-600 × 109/L, n (%) | 16 (4) | 237 (57) |
| More than 600 × 109/L, n (%) | 395 (95) | 72 (17) |
| Median WBC, ×109/L (range) | 9.4 (4.2-34) | 6.7 (3.2-28.9) |
| Less than 10 × 109/L, n (%) | 267 (64) | 371 (89) |
| More than 10 × 109/L, n (%) | 149 (36) | 45 (11) |
| Aspirin-resistant microvascular symptoms, n (%) | ||
| No | 313 (75) | 368 (88) |
| Yes | 103 (25) | 48 (12) |
| Splenomegaly, n (%) | ||
| No | 359 (86) | 381 (92) |
| Yes | 57 (14) | 35 (8) |
PLT indicates platelets.